PDL injects $70M into Durata; Vivus to cut 20 staffers; FDA outlines proper use of Iclusig;

@FierceBiotech: Morningstar analyst ranks the top 11 pharma giants' prospects, putting GSK on top. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis to chop 371 jobs, shutter research center in global R&D shakeup. Story | Follow @JohnCFierce

@DamianFierce: Medtronic looks to widen its renal denervation lead with latest trial. Article | Follow @DamianFierce

@EmilyMFierce: Scientists at startup Sage Therapeutics have discovered a molecule that could treat a wide range of CNS disorders. More | Follow @EmilyMFierce

> PDL BioPharma has agreed to provide Durata ($DRTX) with $70 million in debt financing. The biotech's lead antibiotic is dalbavancin, the subject of an NDA filed in September. Release

> Troubled Vivus ($VVUS) says it will trim its workforce, cutting 20 jobs to save cash. Story

> The FDA has spelled out how Ariad's ($ARIA) cancer drug Iclusig can still be used among patients who are not responding to other therapies. Ariad recently suspended sales of the drug after seeing a serious risk of blood clots among patients taking the drug. Release

Medical Device News

@FierceMedDev: Supreme Court to decide on Medtronic, Boston Scientific patent fight by June. Story | Follow @FierceMedDev

@MarkHFierce: Check out our latest issue of FierceDiagnostics--lots of good stuff and just sent out. Newsletter | Follow @MarkHFierce

> New PillCam approvals accelerate Given Imaging's revenue gains. More

> Medtronic looks to widen its renal denervation lead with latest trial. Story

> Direct Flow snags up to $50M to push heart valve in crowded market. Article

Pharma News

@FiercePharma: Trending now: Novartis eyes animal health sale as first slim-down move: Bloomberg. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Here's yesterday afternoon's Vivus Q3 earnings call transcript. More | Follow @CarlyHFierce

> U.K. caps drug spending, forcing pharma to curtail prices. More

> Novartis plots sales cuts in U.K. amid R&D restructuring. Story

> Will Merck be next to join Big Pharma's asset-sale parade? Article

Drug Delivery News

@MichaelGFierce: Gold nanoparticles first to deliver RNA to brain tumors. More | Follow @MichaelGFierce

> Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. Item

> IBM uses hydrogel to prolong delivery of Roche's Herceptin. More

> Platinum drug delivery method snuffs cancer's power source. Article

> Novo Nordisk wins FDA approval for two automated-dose insulin pens. News

> Study: Arrowhead's hep B RNAi drug could offer 'functional cure'. Report

Diagnostics News

> Cancer Dx test maker Veracyte launches successful IPO. Item

> Ariosa defeats Sequenom in prenatal testing patent battle. More

> Illumina, Natera, Ariosa tests gain contracts with CA's prenatal Dx program. Story

> AutoGenomics pulls IPO plans and mulls possible private offering instead. Article

> PerkinElmer to sell Transgenomic molecular Dx oncology tests overseas. Report

> Alere's new HIV test could gain momentum from Affordable Care Act. News

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.